Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients
Status:
Terminated
Trial end date:
2017-09-22
Target enrollment:
Participant gender:
Summary
Assessment of the safety, tolerability and early signs of efficacy of three times a day
orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on
treatment with Orkambi